Contact:
Silvana Guerci-Lena Manager, Public Relations
sguerci@optos.com
508-787-1437
Optos Software Upgrade Enhances Customer Clinical Capability
5/13/2008
MARLBOROUGH, MA, 13 May 2008 – Optos plc (LSE: OPTS), a leading medical technology company for the design, development, manufacturing and marketing of retinal imaging devices, is today announcing that it has launched an upgraded version of its proprietary retinal imaging software designed to support practitioners in their clinical mandate and improve their practice management capabilities.
V2® Vantage Dx is the next generation software to be released by the Company.
Key features include:
- Exact Disk™ Optic Nerve Enhancement is where the software automatically manipulates the patient’s retinal image to ensure that the optic disk appears in its natural shape and free of any distortion that can be caused in the scanning process.
- 3D Wrap™ is a previously launched interactive patient education tool but it now includes a refractive error capability that enables the doctor to demonstrate to the patient the effects of refractive error and how this affects vision.
- Intraocular Lens (IOL) allows the practitioner to educate cataract surgery patients on the operation of mono-focal and multi-focal IOL’s.
Commenting on the benefits of V2® Vantage Dx, Dr Michael Rothschild, West Georgia Eye Care, Carrolton, Georgia, said:
“Optos is committed to making continuous software and device enhancements that help me provide better care to my patients. A key feature is the Exact Disk™ Optic Nerve Enhancement which provides a round optic nerve and makes it easier to compare existing or developing pathologies.”
Optos’ devices are scalable to accommodate software upgrades. Annual upgrades are part of the Company’s ‘Evergreen Strategy’ which is about supporting customers through new business processes and software packages. This strategy is designed to keep customers on the leading edge of retinal imaging and practice technologies.
Commenting, Thomas W. Butts, Chief Executive Officer, Optos plc, said:
“It is critical that our customers are kept current and refreshed - this new software raises the clinical utility of their patient offering.”
< ENDS >
Enquiries
Optos plc
John McNeil
Company Secretary +44 (0)1383 843 337
Maitland
Neil Bennett +44 (0)20 7379 5151
About Optos Plc
Optos plc is a leading and rapidly growing medical technology company for the design, development, manufacturing and marketing of devices that image the retina, the light-sensitive area at the back of the eye. Optos has commercialised a full range of complementary retinal imaging devices that support different customer segments and patient levels within the eye and healthcare market: P200 is concentrated on wellness screening carried out by optometrists and ophthalmologists; P200C in the advanced clinical optometry and ophthalmology markets; P200MA supports doctors through an advanced medical angiography procedure. All three devices provide practitioners with the benefit of an ultra wide-field high resolution view of the retina, facilitating the early detection, management and treatment of disorders and diseases evidenced in the retina such as glaucoma, diabetic retinopathy and age-related macular degeneration. Retinal imaging can also indicate evidence of non-eye or systemic diseases such as diabetes, hypertension and certain cancers. Optos’ technology provides an unequalled combination of wide-field retinal imaging, speed and convenience for both practitioner and patient and can help save sight and save lives.
Forward-Looking Statements
Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company's current expectations, estimates and projections about its industry, its beliefs and assumptions. Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the Company's control, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.